Joost M. Meijer

Joost M. Meijer

Auto-generated profile, based on publicly available information

Joost M. Meijer

Department of Dermatology, Center of Expertise for Blistering Diseases University of Groningen, University Medical Center Groningen Groningen The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
ESE. Schmidt
E. Schmidt
HRH. Rashid
H. Rashid
Angelo MarzanoAngelo Marzano
Angelo Marzano
ALA. Lamberts
A. Lamberts
GZG. Di Zenzo
G. Di Zenzo
FCF. Caux
F. Caux
This guideline has been initiated by the task forceAutoimmune Blistering Diseasesof the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus‐based guideline that systematically reviewed the literature on mucous membrane pemphigoid (MMP) in the MEDLINE and EMBASE databases until June 2019, with no limitations on language. While the first part of this guideline addressed methodology, as well as epidemiology, terminology, aetiology, clinical presentation and outcome measures in MMP, the second part presents the diagnostics and management of MMP. MMP should be suspected in cases with predominant mucosal lesions. Direct immunofluorescence microscopy to detect tissue‐bound IgG, IgA and/or complement C3, combined with serological testing for circulating autoantibodies are recommended. In most patients, serum autoantibodies are present only in low levels and in variable proportions, depending on the clinical sites involved. Circulating autoantibodies are determined by indirect IF assays using tissue substrates, or ELISA using different recombinant forms of the target antigens or immunoblotting using different substrates. The major target antigen in MMP is type XVII collagen (BP180), although in 10–25% of patients laminin 332 is recognized. In 25–30% of MMP patients with anti‐laminin 332 reactivity, malignancies have been associated. As first‐line treatment of mild/moderate MMP, dapsone, methotrexate or tetracyclines and/or topical corticosteroids are recommended. For severe MMP, dapsone and oral or intravenous cyclophosphamide and/or oral corticosteroids are recommended as first‐line regimens. Additional recommendations are given, tailored to treatment of single‐site MMP such as oral, ocular, laryngeal, oesophageal and genital MMP, as well as the diagnosis of ocular MMP. Treatment recommendations are limited by the complete lack of high‐quality randomized controlled trials.

10 July 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
HRH. Rashid
H. Rashid
ALA. Lamberts
A. Lamberts
LBL. Borradori
L. Borradori
SAS. Alberti‐Violetti
S. Alberti‐Violetti
RBR.J. Barry
R.J. Barry
BHB. Horváth
B. Horváth
This guideline on mucous membrane pemphigoid (MMP) has been elaborated by the Task Force for Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology (EADV) with a contribution of physicians from all relevant disciplines and patient organizations. It is a S3 consensus‐based guideline encompassing a systematic review of the literature until June 2019 in the MEDLINE and EMBASE databases. This first part covers methodology, the clinical definition of MMP, epidemiology, MMP subtypes, immunopathological characteristics, disease assessment and outcome scores. MMP describes a group of autoimmune skin and mucous membrane blistering diseases, characterized by a chronic course and by predominant involvement of the mucous membranes, such as the oral, ocular, nasal, nasopharyngeal, anogenital, laryngeal and oesophageal mucosa. MMP patients may present with mono‐ or multisite involvement. Patients’ autoantibodies have been shown to be predominantly directed against BP180 (also called BPAG2, type XVII collagen), BP230, laminin 332 and type VII collagen, components of junctional adhesion complexes promoting epithelial stromal attachment in stratified epithelia. Various disease assessment scores are available, including the Mucous Membrane Pemphigoid Disease Area Index (MMPDAI), the Autoimmune Bullous Skin disorder Intensity Score (ABSIS), the ‘Cicatrising Conjunctivitis Assessment Tool’ and the Oral Disease Severity Score (ODSS). Patient‐reported outcome measurements (PROMs), including DLQI, ABQOL and TABQOL, can be used for assessment of quality of life to evaluate the effectiveness of therapeutic interventions and monitor disease course.

25 March 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
EAEmiliano Antiga
Emiliano Antiga
RBRikke Bech
Rikke Bech
RMRoberto Maglie
Roberto Maglie
GGGiovanni Genovese
Giovanni Genovese
LBLuca Borradori
Luca Borradori
Angelo MarzanoAngelo Marzano
Angelo Marzano
Background: Paraneoplastic pemphigus (PNP), also called paraneoplastic autoimmune multiorgan syndrome (PAMS), is a rare autoimmune disease with mucocutaneous and multi‐organ involvement. PNP/PAMS is typically associated with lymphoproliferative or haematological malignancies, and less frequently with solid malignancies. The mortality rate of PNP/PAMS is elevated owing to the increased risk of severe infections and disease‐associated complications, such as bronchiolitis obliterans.Objectives: These guidelines summarize evidence‐based and expert‐based recommendations (S2k level) for the clinical characterization, diagnosis and management of PNP/PAMS. They have been initiated by the Task Force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology with the contribution of physicians from all relevant disciplines. The degree of consent among all task force members was included.Results: Chronic severe mucositis and polymorphic skin lesions are clue clinical characteristics of PNP/PAMS. A complete assessment of the patient with suspected PNP/PAMS, requiring histopathological study and immunopathological investigations, including direct and indirect immunofluorescence, ELISA and, where available, immunoblotting/immunoprecipitation, is recommended to achieve a diagnosis of PNP/PAMS. Detection of anti‐envoplakin antibodies and/or circulating antibodies binding to the rat bladder epithelium at indirect immunofluorescence is the most specific tool for the diagnosis of PNP/PAMS in a patient with compatible clinical and anamnestic features. Treatment of PNP/PAMS is highly challenging. Systemic steroids up to 1.5 mg/kg/day are recommended as first‐line option. Rituximab is also recommended in patients with PNP/PAMS secondary to lymphoproliferative conditions but might also be considered in cases of PNP/PAMS associated with solid tumours. A multidisciplinary approach involving pneumologists, ophthalmologists and onco‐haematologists is recommended for optimal management of the patients.Conclusions: These are the first European guidelines for the diagnosis and management of PNP/PAMS. Diagnostic criteria and therapeutic recommendations will require further validation by prospective studies.

15 October 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
ALA. Lamberts
A. Lamberts
NKN. Kotnik
N. Kotnik
GDGilles F.H. Diercks
Gilles F.H. Diercks
JMJ.M. Meijer
J.M. Meijer
GZGiovanni Di Zenzo
Giovanni Di Zenzo
BHB. Horváth
B. Horváth
Background: Non‐bullous pemphigoid (NBP) is a pemphigoid variant which frequently resembles other pruritic skin diseases. In contrast with bullous pemphigoid (BP), blisters are absent. In BP, previous studies showed that IgE autoantibodies may be involved in its pathogenesis. IgE‐activated mast cells, basophils and eosinophils may participate in BP by inducing pruritus and possibly blister formation, although the differential role of IgE in NBP compared with BP has not yet been described.Objective: To assess IgE in serum and skin of NBP and BP patients.Methods: We examined total IgE and pemphigoid‐specific IgE in the serum of 68 NBP and 50 BP patients by enzyme‐linked immunosorbent assay (ELISA). Sera of 25 pemphigus patients and 25 elderly patients with pruritus were included as controls. Skin biopsies of 14 NBP and 14 BP patients with the highest IgE titres to NC16A were stained for IgE by immunofluorescence techniques.Results: Total IgE was elevated in 63% of NBP and 60% of BP patients, and in 20% of pemphigus controls, as well as 60% of elderly controls. IgE ELISAs were more frequently positive in BP than in NBP (NC16A 18% vs. 9%, P = 0.139; BP230 34% vs. 22%, P = 0.149). IgE ELISAs for NC16A and BP230 were positive in 8% and 20% of elderly controls, respectively, while all pemphigus controls were negative. Two of 28 biopsies (7%; one NBP, one BP) showed linear IgE along the basement membrane zone, while in most biopsies (71% NBP; 86% BP) IgE was bound to dermal cells.Conclusion: Since IgE was present in the serum and skin of both NBP and BP patients, this supports IgE‐dependent mechanisms common to both diseases, such as pruritus. However, it remains to be elucidated whether IgE contributes to blister formation in BP.

11 March 2014 in Journal of Computer Assisted Learning
Verified
Journal Article
Closed access
PDF file
IHI. Heemskerk
I. Heemskerk
EKE. Kuiper
E. Kuiper
JMJ. Meijer
J. Meijer

25 June 2021 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
VHV. Hébert
V. Hébert
SBS. Bastos
S. Bastos
KDKossara Drenovska
Kossara Drenovska
JMJ. Meijer
J. Meijer
SIS. Ingen-Housz-Oro
S. Ingen-Housz-Oro
TEThe French study Group on auto immune bullous skin diseases, the auto immune bullous skin disease task force of the EADV
The French study Group on auto immune bullous skin diseases, the auto immune bullous skin disease task force of the EADV
Background European guidelines propose a 0.5 mg/kg/day dose of oral prednisone as initial treatment of bullous pemphigoid (BP). We assessed the safety and efficacy of this regimen depending on BP extent, and patients’general condition. Methods In a prospective international study, we consecutively included all patients diagnosed with BP. Patients received a 0.5 mg/kg/day dose of prednisone, then gradually tapered 15 days after disease control, with the aim of stopping prednisone or maintaining minimal treatment (0.1 mg/kg/day) within 6 months after the start of treatment. The two co-primary endpoints were control of disease activity at Day21 and one-year overall survival. Disease severity was assessed according to Bullous-Pemphigoid-Disease-Area-Index (BPDAI) score. Results Between 2015 and 2017, 198 patients were included. The final analysis comprised 190 patients with a mean age of 80.9±9.1 years. Control of disease activity was achieved at Day21 in 119 patients (62.6%; 95%CI=55.3-69.5%): 18 of 24 (75.0%; 95%CI=53.3-90.2%), 75 of 110 (68.2%; 95%CI=59.2-77.3%) and 26 of 56 (46.4%; 95%CI=33.0-60.3%) patients had mild, moderate and severe BP, respectively (p=0.0218). Thirty-two patients died. The overall Kaplan-Meier one-year survival was 82.6 % (95%CI=76.3-87.4%) corresponding to 90.9%, 83.0% and 80.0% rates in patients with mild, moderate and severe BP, respectively (p=0.5). Thresholds of 49-points for BPDAI score and 70-points for Karnofsky score yielded maximal Youden index values with respect to disease control at Day21 and one-year survival, respectively. Conclusion A 0.5 mg/kg/day dose of prednisone is a valuable therapeutic option in patients with mild/moderate BP whose general condition allows them to be autonomous.